You’d have to have been under a rock to have missed the fanfare about the front-runner vaccine candidates lately. One of the top three racing to the finish line is the offering from Oxford/AstraZeneca. Their product is a LIVE attenuated vaccine using a monkey adenovirus with a SARS-CoV-2 spike protein genetically engineered onto it.
Dr Wiles explains in this article from Auckland University, that other vaccines using this kind of chimeric technology include the dengue fever jab. She says:
“A variation on the live-attenuated vaccine approach is to develop what is known as a chimeric vaccine. For this, we use the backbone of a less harmful or weakened microbe but engineer it to contain the protein(s) of the harmful microbe that the immune system recognises. Again, there are vaccines like this already in use in people, including for Ebola and dengue fever, and they have been shown to trigger really good immune responses.” 
Do you know what else the dengue vaccine was great at doing? Creating Antibody Dependent Enhancement (ADE). What’s that, you ask? That’s when your immune system goes a bit overboard in its response and the infection is enhanced, leading to death in some cases.  In the case of Dengvaxia in the Philippines, many hundreds of thousands of children were given this jab before they realised that they were actually INCREASING their risk of harm. It is reported that 130 children DIED as a result of receiving this vaccine. 
With no longer-term studies available for the current portfolio of vaccines in development, how will we know something similar won’t happen with this COVID-19 vaccine? Given this one will be going into the arms of hundreds of millions (if not billions) of people, wouldn’t open discussion about these issues be a good idea? We think it is.
Also, consider a scenario where coercion or compulsion is used to ensure uptake of these experimental biologics and ask yourself how ethical that might be? Exactly who will be responsible for any fall out? One thing we know for sure, it won’t be the manufacturers.
“AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries with which it has struck supply agreements, a senior executive told Reuters….“This is a unique situation where we as a company simply cannot take the risk if in … four years the vaccine is showing side effects,” Ruud Dobber, a member of Astra’s senior executive team, told Reuters.”